R&D

New Vaccine Unexpectedly Suppresses HIV infection Monkeys

New Vaccine Unexpectedly Suppresses HIV infection Monkeys

Written by on September 1, 2014 in Featured on App, News, R&D with 0 Comments

A new vaccine has been found to stop rhesus macaque moneys from infection with SIV, the monkey form of the HIV virus An international research team, with scientists based in Paris-Descartes University in France, as well as the University of Chinese Medicine in Guangzhou, China, has developed a new orally administered vaccine that was found […]

Continue Reading

How a Genetic Analysis of Dengue Led to the Vaccine Candidate

How a Genetic Analysis of Dengue Led to the Vaccine Candidate

Written by on August 29, 2014 in Featured on App, News, R&D with 0 Comments

Replikins explains how an analysis of gene structures in the dengue virus led to the development of a vaccine candidate Replikins Ltd, the company that first identified a group of peptides called Replikins, has announced that one of its studies on the genetic structure of the dengue virus has been instrumental in the development of […]

Continue Reading

Therapeutic

Japan May Provide West African Countries With Unapproved Ebola Treatment

Japan May Provide West African Countries With Unapproved Ebola Treatment

Written by on August 27, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

The Japanese government is ready to provide Ebola afflicted countries an experimental drug that has not yet been approved by the WHO On Monday the 27th of August, Japan’s Chief Cabinet Secretary Yoshihide Suga announced that the country is willing to donate a flu drug called Favipiravir to aid the Ebola crisis in west Africa. […]

Continue Reading

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Written by on August 22, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer […]

Continue Reading

Prophylactic

The HPV Cancer Vaccine: Two Doses May Be Enough

The HPV Cancer Vaccine: Two Doses May Be Enough

Written by on August 28, 2014 in Featured on App, News, Prophylactic Vaccines, Supply Chain with 0 Comments

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus On Monday the 25th of August, the 29th International Papillomavirus Conference came to a close in Seattle, USA. Amongst the most hotly debated topics at the conference was lowering the number of doses of the […]

Continue Reading

Polio Strain Resistant to Vaccine was Responsible for 2010 Congo Outbreak

Polio Strain Resistant to Vaccine was Responsible for 2010 Congo Outbreak

Written by on August 26, 2014 in Featured on App, News, Prophylactic Vaccines with 0 Comments

A vaccine resistant mutation of the poliovirus was the cause of the major 2010 polio outbreak in DR Congo Research published in the scientific journal ‘Proceedings of the National Academy of Sciences‘ has shown that a mutated strain of the poliovirus was responsible for a 2010 outbreak in the Democratic Republic of Congo, which claimed […]

Continue Reading

Flu

A Universal Flu Vaccine: Could Rare Flu Strains be the Answer?

A Universal Flu Vaccine: Could Rare Flu Strains be the Answer?

Written by on August 27, 2014 in Antibodies, Featured on App, Flu, News with 0 Comments

Research suggests that vaccinations against rare strains of bird flu would be highly effective against a broad range of influenza viruses A study by the Emory Vaccine Centre in Atlanta has found that exposure to rare and uncommon flu strains results in the production of broadly effective antibodies. The study thus begs the question: should […]

Continue Reading

FDA Approves AFLURIA Flu Vaccine To Be Administered With Pharmajet’s Needle-Free Injector

FDA Approves AFLURIA Flu Vaccine To Be Administered With Pharmajet’s Needle-Free Injector

Written by on August 22, 2014 in Featured on App, Flu, News with 0 Comments

The future of vaccine administration my change forever with Pharmajet’s needle-free injector The FDA has approved the first needle-free drug system for the delivery of bioCSL’s influenza vaccine AFLURIA. Now, doctors and other health care workers can chose whether they want to administer the influenza vaccine via a needle or through PharmaJet’s needle-free system. Ron […]

Continue Reading

Regulation & Policy

Focus on the Children: New study finds key to improving vaccine coverage

Focus on the Children: New study finds key to improving vaccine coverage

Written by on August 22, 2014 in Regulation and Policy with 0 Comments

A new report shows the power of child orientated pro-vaccine messages when trying to convince parents to vaccinate their children A new study, published earlier this month in Pediatrics, has shown that, when trying to convince parents of young children, that emphasizing the benefits to their infant is more effective than pushing home the societal benefits of […]

Continue Reading

FDA Enables Potential Use of Experimental Tekmira Vaccine on Ebola Patients

FDA Enables Potential Use of Experimental Tekmira Vaccine on Ebola Patients

Written by on August 11, 2014 in Featured on App, Regulation and Policy with 0 Comments

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients The FDA has lifted a temporary ‘halt in research’ placed on the Ebola drug that has been developed by Canadian company Tekmira Pharmaceuticals. The lift of this hold means that the experimental […]

Continue Reading

Emerging Markets

The State of the Art of Electronic Health Records – Infographic

The State of the Art of Electronic Health Records – Infographic

Written by on August 22, 2014 in Emerging Markets, News with 0 Comments

In the next 10 years, data science and software will do more for medicine than all of the biological sciences together” Vinod Khosla, venture capitalist Last year, Vaccine Nation reported on research suggesting that the adoption of Electronic Health Records (EHR) could dramatically increase the ability of public health authorities to track immunizations amongst patient. […]

Continue Reading

Ebola Treatment Centre: An Interactive Guide

Ebola Treatment Centre: An Interactive Guide

Written by on August 19, 2014 in Emerging Markets, Featured on App, News with 0 Comments

The Golden Number: 42 Days With a while to wait before we see an approved Ebola vaccine become available, the virus must be effectively contained in order to see an end to the outbreak. The time it takes for symptoms to appear after exposure to the virus is known as the incubation period – and […]

Continue Reading

Supply Chain

Lost Small Pox Vials and Anthrax Mishaps

Lost Small Pox Vials and Anthrax Mishaps

Written by on July 15, 2014 in News, Regulation and Policy, Supply Chain with 0 Comments

  Will small pox and anthrax biosafety concerns undermine vital research? Last week the US Centres for Disease Control and Prevention announced that 6 small pox vials had been discovered on the 1st of July during the clearing out of an old laboratory at the Nationality Institute of Health’s (NIH) Bethesda campus, Maryland. The six […]

Continue Reading

Ensuring Critical Vaccine Supply: Raw Materials Perspective

Ensuring Critical Vaccine Supply: Raw Materials Perspective

Written by on June 25, 2014 in Features & Downloads, Supply Chain with 0 Comments

Frank Appel, Senior Manager, Europe Vaccines Segments, Process Solutions, Merck Millipore joined us last year at the World Vaccine Congress Europe to present on ‘Ensuring Critical Vaccine Supply: Raw Materials Perspective.’ Download this presentation now to find out more about: Ensuring Safety: A real challenge & business risk The Reality of Upstream Contamination BioSafety Strategy […]

Continue Reading

Strategy and Partnering

Pfizer Buys Baxter’s Vaccine Unit For $635 million

Pfizer Buys Baxter’s Vaccine Unit For $635 million

On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International’s Vaccines Unit Worth $635 Million The deal will give Pfizer access to Baxter’s meningitis and encephalitis vaccine. Pfizer will also get access to part of a Baxter’s production facility in Austria, where the vaccines are made. The deal is expected to be carried and closes […]

Continue Reading

How to choose your perfect CRO partner

How to choose your perfect CRO partner

Deciding upon the correct CRO is a crucial element of each vaccine’s development for the likes of biotech’s and pharma, concerned with outsourcing their research. This eBook answers the all-important question of how to choose your perfect CRO partner by providing a checklist of the top 10 criteria that sponsors use for selecting CROs. Thereby […]

Continue Reading

Other Recent Posts

Nasal Spray Flu Vaccine in Kids Can Trim Caseload And Be Cost-Effective, Especially in a Bad Season, Study Finds

With flu vaccination season upon us, the question arises, shot or nasal spray? For children, a nasal spray might be an easier option, and a new study just published in The American Journal of Pharmacy Benefits shows that if a moderate to harsh flu season is expected, it’s a cost-effective choice, too. August 31, 2014 […]

Continue Reading

Ebola vaccine trials fast-tracked by international consortium

Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine August 28, 2014 A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has […]

Continue Reading

Pfizer’s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation

August 28, 2014 Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C. difficile is a growing, difficult-to-treat […]

Continue Reading

Top
Geolocation